Vedolizumab
- Generic Name
- Vedolizumab
- Brand Names
- Entyvio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 943609-66-3
- Unique Ingredient Identifier
- 9RV78Q2002
- Background
Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative colitis or Crohn's disease. α4β7 integrin facilitates the interaction between lymphocytes and gut endothelial cells through the α4β7 integrin-MAdCAM1 intera...
- Indication
Vedolizumab is indicated for adult patients with moderately to severely active Ulcerative Colitis or Crohn’s disease.
- Associated Conditions
- Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis
- Associated Therapies
- -
Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases
- Conditions
- Interventions
- First Posted Date
- 2016-08-10
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Shaare Zedek Medical Center
- Target Recruit Count
- 142
- Registration Number
- NCT02862132
- Locations
- 🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇸🇮University Children's Hospital Ljubljana, Ljubljana, Slovenia
🇮🇱Assaf Harofeh, Tzrifin, Israel
Vedolizumab Post Op Study
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2020-05-14
- Lead Sponsor
- Marc Schwartz
- Registration Number
- NCT02834754
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Effectiveness of Vedolizumab in CD Patients Naïve to Anti-TNF
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2018-05-14
- Lead Sponsor
- Universita degli Studi di Genova
- Registration Number
- NCT02820493
A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
- Conditions
- Interventions
- First Posted Date
- 2016-06-03
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 102
- Registration Number
- NCT02790138
- Locations
- 🇧🇪
UZ Leuven - University Hospital Gasthuisberg, Leuven, Belgium
🇳🇱Academic Medical Center, Amsterdam, Netherlands
🇮🇹Azienda Ospedaliera S. Orsola-Malpighi, Bologna, Italy
Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2023-06-15
- Target Recruit Count
- 47
- Registration Number
- NCT02768532
- Locations
- 🇫🇷
Chu Saint Etienne, Saint Etienne, France
🇫🇷CHU Kremlin Bicetre, Paris, Le Kremlin-Bicêtre, France
🇫🇷CHU Lyon-Sud, Hospices Civils de Lyon, PIERRE-BENITE, Pierre Bénite, France
Triple Combination Therapy in High Risk Crohn's Disease (CD)
- Conditions
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 55
- Registration Number
- NCT02764762
- Locations
- 🇺🇸
Cotton O'Neil Clinical Research, Topeka, Kansas, United States
🇺🇸University of Mississippi Medical Center, Jackson, Mississippi, United States
🇨🇦PerCuro Clinical Research Ltd, Victoria, British Columbia, Canada
Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study
- Conditions
- Interventions
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- Takeda
- Registration Number
- NCT02760615
- Locations
- 🇺🇸
WCCT, Cypress, California, United States
🇺🇸QPS MRA, Miami, Florida, United States
Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 331
- Registration Number
- NCT02743806
- Locations
- 🇦🇺
The Canberra Hospital, Garran, Australian Capital Territory, Australia
🇦🇺Western Hospital, Footscray, Victoria, Australia
🇦🇺Box Hill Hospital, Box Hill, Australia
Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT
- Conditions
- Interventions
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2019-08-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 24
- Registration Number
- NCT02728895
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸OSU - James Comprehensive Cancer Center, Columbus, Ohio, United States
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02723006
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.